Literature DB >> 8523565

Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.

K J Fisher1, G P Gao, M D Weitzman, R DeMatteo, J F Burda, J M Wilson.   

Abstract

Adeno-associated virus is an integrating DNA parvovirus with the potential to be an important vehicle for somatic gene therapy. A potential barrier, however, is the low transduction efficiencies of recombinant adeno-associated virus (rAAV) vectors. We show in this report that adenovirus dramatically enhances rAAV transduction in vitro in a way that is dependent on expression of early region 1 and 4 (E1 and E4, respectively) genes and directly proportional to the appearance of double-stranded replicative forms of the rAAV genome. Expression of the open reading frame 6 protein from E4 in the absence of E1 accomplished a similar but attenuated effect. The helper activity of adenovirus E1 and E4 for rAAV gene transfer was similarly demonstrated in vivo by using murine models of liver- and lung-directed gene therapy. Our data indicate that conversion of a single-stranded rAAV genome to a duplex intermediate limits transduction and usefulness for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523565      PMCID: PMC189840     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  SOS response in mammalian cells.

Authors:  A Sarasin
Journal:  Cancer Invest       Date:  1985       Impact factor: 2.176

2.  Biochemical studies on adenovirus multiplication. IX. Chemical and base composition analysis of 28 human adenoviruses.

Authors:  M Piña; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1965-08       Impact factor: 11.205

3.  Adenovirus early gene regulation and the adeno-associated virus helper effect.

Authors:  W D Richardson; H Westphal
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

4.  Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff.

Authors:  D N Halbert; J R Cutt; T Shenk
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

5.  Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adeno-associated virus.

Authors:  W D Richardson; H Westphal
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

6.  Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants.

Authors:  P L Hermonat; M A Labow; R Wright; K I Berns; N Muzyczka
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

7.  Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function.

Authors:  J D Tratschin; I L Miller; B J Carter
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

8.  Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis.

Authors:  L E Babiss; H S Ginsberg
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

9.  Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein.

Authors:  S A Rice; D F Klessig
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

10.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

View more
  188 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

3.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.

Authors:  J Hansen; K Qing; H J Kwon; C Mah; A Srivastava
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 5.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

6.  Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.

Authors:  M A Passini; J H Wolfe
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 9.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

10.  Adeno-associated viruses can induce phosphorylation of eIF2alpha via PKR activation, which can be overcome by helper adenovirus type 5 virus-associated RNA.

Authors:  Ramnath Nayak; David J Pintel
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.